Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712158 | 1.00 | MLYCD (0.45) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL21500605 | 0.85 | KMT2A (0.39) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL21265229 | 0.83 | CA12 (0.46) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL29210349 | 0.83 | CA12 (0.46) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL16750522 | 0.82 | CA12 (0.48) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL1396652 | 0.81 | MLYCD (0.50) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL1396649 | 0.81 | MLYCD (0.50) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL20671047 | 0.81 | MLYCD (0.44) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL20660702 | 0.81 | MLYCD (0.44) | MLYCDCA12CA1CA2CA7 | |
| SCHEMBL15959223 | 0.80 | TRPV1 (0.47) | MLYCDCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258354-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3749669-B3 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3749669-B1 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039955-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11548867-B2 | Amido compounds as AhR modulators | IDEA YA BIOSCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548867-B2 | Amido compounds as AhR modulators | IDEA YA BIOSCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11407764-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407764-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9796706-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9073891-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MLYCD 1286/4885CA12 4434/4885CA1 1391/4885 |
| US-11407764-B2 | AhR modulators | AHR, ARNT, RORB | MLYCD 1725/4885CA12 4726/4885CA1 4660/4885 |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MLYCD 1286/4885CA12 4434/4885CA1 1391/4885 |
| US-20230039955-A1 | AhR MODULATORS | AHR, ARNT, RORB | MLYCD 1712/4885CA12 4719/4885CA1 4656/4885 |
| US-12258354-B2 | AhR modulators | AHR, ARNT, RORB | MLYCD 1725/4885CA12 4726/4885CA1 4660/4885 |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MLYCD 1286/4885CA12 4434/4885CA1 1391/4885 |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | AHR, MCL1, ARNT | MLYCD 1007/4885CA12 4127/4885CA1 3574/4885 |
| US-11548867-B2 | Amido compounds as AhR modulators | AHR, ARNT, RXRB | MLYCD 1498/4885CA12 4639/4885CA1 4613/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | MLYCD 1286/4885CA12 4434/4885CA1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.